NLC India Q2 Profit Drops 9.5% to Rs 982 Cr
By Rediff Money Desk, New Delhi Oct 25, 2024 15:28
NLC India's Q2 profit declined by 9.5% to Rs 982.41 crore, while revenue increased to Rs 3,657.27 crore. Read more about the company's performance.
New Delhi, Oct 25 (PTI) State-owned NLC India Ltd on Friday reported a 9.5 per cent decline in consolidated profit at Rs 982.41 crore for the quarter ended September 30, 2024.
The company had posted a consolidated profit of Rs 1,085.93 crore in the year-ago period, NLC India Ltd said in a regulatory filing.
However, the revenue from operations in the July-September quarter increased to Rs 3,657.27 crore, over Rs 2,977.53 crore in the year-ago period.
NLC India is a navratna company under the Ministry of Coal. Its core business is mining and power generation.
The company had posted a consolidated profit of Rs 1,085.93 crore in the year-ago period, NLC India Ltd said in a regulatory filing.
However, the revenue from operations in the July-September quarter increased to Rs 3,657.27 crore, over Rs 2,977.53 crore in the year-ago period.
NLC India is a navratna company under the Ministry of Coal. Its core business is mining and power generation.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.95 (+ 9.10)
- 188579011
- Thinkink Picturez
- 1.28 ( -4.48)
- 30136876
- Standard Capital
- 0.94 (+ 2.17)
- 16517445
- AvanceTechnologies
- 0.78 ( -2.50)
- 15415869
- Srestha Finvest
- 0.70 (+ 1.45)
- 15301981
MORE NEWS
Aurum PropTech Loss Narrows in Dec Quarter,...
Aurum PropTech's consolidated net loss narrowed to Rs 6.60 crore in the December...
Zomato Shares Plunge 4% as Q3 Profit Drops
Zomato's shares fell nearly 4% on Monday after the food delivery company reported a...
Strides Pharma Gets USFDA Nod for Generic Pain...
Strides Pharma Science's Singapore arm receives USFDA approval for its generic...